Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not produce measurable improvements in glucose tolerance, gut microbiome composition, or inflammatory markers in sedentary adults with overweight or obesity. While...
Mira-55 Shows No THC- or Rimonabant-Linked CNS Side Effects in Preclinical Tests
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Cb1 ReceptorsDrug DevelopmentMetabolic HealthCns SafetyPharmaceutical Research Why This MattersMIRA-55 represents a potential breakthrough in...
Cannabidiol & Glucose Tolerance: Clinical Evidence Review
Clinical Takeaway In this pilot study, short-term low-dose oral CBD did not significantly improve glucose tolerance or produce measurable changes in the gut microbiome in sedentary adults with overweight or obesity. While...
Cannabidiol & Glucose Tolerance: Clinical Evidence Review
Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not measurably improve glucose tolerance or beneficially alter the gut microbiome in sedentary adults with overweight or obesity. While animal research...
endocannabinoid system clinical research: CBD & Metabolic Health
Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not produce measurable improvements in glucose tolerance, gut microbiome composition, or inflammation markers in sedentary adults with overweight or obesity. While...
endocannabinoid system clinical research: CBD & Metabolic Health
Clinical Takeaway In this pilot study, short-term low-dose oral CBD did not improve glucose tolerance or meaningfully alter gut microbiome composition in sedentary adults with overweight or obesity. While epidemiological data suggest...
Cannabis compounds could reverse disease affecting one-third of adults – Fox News
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyCBD Dr. Caplan’s Take “What we’re seeing in the preclinical work on cannabinoids and metabolic...
Research claims compounds found in cannabis could reverse disease that affects one-third of adults
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchSafetyTHC Clinical Summary This article reports on UC San Francisco research investigating whether cannabis compounds...
Cannabis compounds could reverse disease affecting one-third of adults – New York Post
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDAgingSafety Clinical Summary Clinical Summary Recent research indicates that non-psychoactive cannabis compounds may have therapeutic...
Drugs inhibiting cannabinoid receptor type-1 can reduce obesity-associated steatohepatitis
Cannabinoid receptor type 1 antagonist inhibits progression of obesity‐associated nonalcoholic steatohepatitis in a mouse model by remodulating immune system disturbances In Summary: Steatohepatitis, a condition often associated with type 2 diabetes and...